Importance of chemical reduction in plasma and serum homocysteine analysis.

Featured Article: Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine in plasma and urine. Clin Chem 1985;31:624 – 8. In 1977, as part of the research on which I based my PhD thesis, I purified S-adenosylhomocysteine hydrolase to homogeneity, and in the years that followed, my colleagues and I studied its role in the metabolism of S-adenosylhomocysteine in cells and animals treated with adenosine analogs. During these experiments, we gained knowledge about the catalytic properties of the enzyme, which enabled us to construct an enzymic assay for homocysteine in rat and mouse tissues as well as in plasma from mice (1 ). When this methodological work was being carried out in 1982, data on homocysteine were sparse and addressed limited aspects of homocysteine in health and disease, such as homocyst(e)ine in patients with the inborn error of homocystinuria, increased homocyst(e)ine (often the homocysteine-cysteine mixed disulfide) in patients with cardiovascular disease (CVD), and the so-called methionine dependence of some cancer cells (2 ). In the paper on homocysteine in tissues (1 ), we concluded that the method “should stimulate clinical investigations on homocysteine in plasma of humans under various pathological conditions and of patients receiving therapy with drugs interfering with one-carbon metabolism.” To accomplish these goals, we had to modify the assay to be able to measure homocysteine in human plasma or serum, in which this aminothiol undergoes disulfide-exchange reactions with cysteine and plasma proteins. Disulfide-exchange reactions also take place in vitro in plasma or serum samples, causing an artificial decrease in free, non–protein-bound homocysteine during storage. These problems were overcome by use of the radioenzymic assay described in the 1985 report highlighted here. The assay measures total homocysteine (tHcy), which is the sum of all homocysteine species (reduced and mixed disulfides with cysteine and albumin) after conversion to homocysteine by chemical reduction. Later, we and other investigators developed additional assays for tHcy, including methods based on HPLC and fluorescence detection, HPLC-MS/MS, GC-MS, and enzymatic-based immunoassays (3 ). The novel methods for tHcy also had higher throughput and better precision than methods based on a conventional amino-acid analyzer. These improvements enabled us to carry out clinical studies using large numbers of stored samples. We first addressed the question of whether tHcy could serve as a marker of folate status in patients with psoriasis, rheumatoid arthritis, or cancer who were treated with a wide range of doses of the antifolate agent methotrexate (3 ). From the late 1980s there was a growing interest in tHcy as a marker of folate or cobalamin deficiency, as an indicator of unhealthy lifestyle, and as a risk factor for CVD (3 ). Numerous case-control and prospective studies on tHcy and CVD were published, and demonstrated increased CVD risk associated with increased tHcy. These results inspired the planning of intervention studies on CVD risk and decreasing tHcy with Bvitamins. A few years later, associations of increased tHcy with other diseases were reported, including dementia, impaired cognitive function, adverse pregnancy outcomes, neural tube defects, and (recently) osteoporosis. The first intervention studies on decreasing tHcy by B-vitamin supplementation have been completed, but the results are inconsistent (4 ), most demonstrating no protection against CVD in patients followed for up to 3 years, and possible protection against stroke from folic acid treatment lasting more than 3 years. The development of methods to measure tHcy in serum or plasma, including the radioenzymic assay, created the methodological foundation for numerous population-based and clinical studies on 1 Section for Pharmacology, Institute of Medicine, University of Bergen and Haukeland Hospital, Bergen, Norway. 2 This paper has been cited more than 235 times since publication. Address correspondence to this author at: Section for Pharmacology, Institute of Medicine, Armauer Hanssens hus, University of Bergen, 5021 Bergen, Norway. Fax 47-55-97 4605; e-mail [email protected]. Received November 14, 2007; accepted November 14, 2007. Previously published online at DOI: 10.1373/clinchem.2007.100438 Clinical Chemistry 54:6 1085–1086 (2008) Citation Classic